Steroids and protein-conjugates thereof
US-2024101594-A1 · Mar 28, 2024 · US
US11801310B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11801310-B2 |
| Application number | US-201816232601-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 26, 2018 |
| Priority date | Dec 26, 2017 |
| Publication date | Oct 31, 2023 |
| Grant date | Oct 31, 2023 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A composition for improving the solubility of poorly soluble substances is provided. The composition includes about 40-99.5% by weight of cyclodextrin and/or derivatives thereof; about 0.05-10% by weight of at least one water-soluble polymer; and about 0.05-60% by weight of at least one water-soluble stabilizer.
Opening claim text (preview).
What is claimed is: 1. A composition for improving the solubility of poorly soluble substances, comprising: 40-99.5% by weight of cyclodextrin and/or a derivative thereof; 0.05-10% by weight of at least one water-soluble polymer; and 0.05-20% by weight of at least one water-soluble stabilizer, wherein the at least one water-soluble stabilizer comprises adenine or guanine. 2. The composition for improving the solubility of poorly soluble substances as claimed in claim 1 , wherein the cyclodextrin comprises α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, δ-cyclodextrin or a combination thereof. 3. The composition for improving the solubility of poorly soluble substances as claimed in claim 1 , wherein the derivative of cyclodextrin comprises hydroxypropyl modified cyclodextrin, succinyl modified cyclodextrin, methyl modified cyclodextrin or a combination thereof. 4. The composition for improving the solubility of poorly soluble substances as claimed in claim 3 , wherein the hydroxypropyl modified cyclodextrin comprises hydroxypropyl-γ-cyclodextrin (hydroxypropyl-γ-CD). 5. The composition for improving the solubility of poorly soluble substances as claimed in claim 1 , wherein the at least one water-soluble polymer comprises hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose, carboxymethyl cellulose (CMC), polyvinylpyrrolidone, (PVP), polyvinyl alcohol, poly(ethylene glycol)-poly(propylene glycol)-poly(ethylene glycol) (PEG-PPG-PEG (ABA)) triblock copolymer or a combination thereof.
using cyclodextrin (cyclodextrins used as simple excipients A61K47/40) · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Eye, e.g. artificial tears · CPC title
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
Solutions {(composition of solutions A61K47/00)} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.